IL-4 and IL-13 blocking peptide (Synairgen)

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug NameIL-4 and IL-13 blocking peptide (Synairgen)
Drug Alias NameIL-4 and IL-13 blocking peptide (University of Southampton)
ClassificationBiologics > Protein drugs > Recombinant polypeptide
Mechanisms of ActionInterleukin 13 receptor inhibitorsInterleukin-4 receptors inhibitors
TargetsInterleukin 13 receptorInterleukin-4 receptors
Therapy Area/IndicationsAsthma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited Kingdom
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesUniversity Of Southampton
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSynairgenUniversity Of Southampton
Active IndicationsN/A
Inactive IndicationsAsthma

Other Information

ATC CodeN/A
Related LinksN/A